抗凝因子蛋白C在肿瘤患者中的检测及其临床意义  

Detection of anticoagulant factor protein C and its clinical significance in patients with malignant tumor

作　　者：何旭华[1] 王振生[1] 李翠琴[1] 徐根波[1] 徐潍生 陈宗凡[2] 杨骅[3] 周明山[4] 郑树[3] 

机构地区：[1]浙江医科大学附属二院血液病研究室 [2]浙江医科大学附属二院血库 [3]浙江医科大学肿瘤研究所 [4]浙医一院肿瘤外科

出　　处：《实用肿瘤杂志》1989年第1期19-22,共4页Journal of Practical Oncology

摘　　要：蛋白C(PC)是新近发现的血浆抗凝因子,在高凝状态性疾病和血栓性疾病的发生发展中起重要作用。PC在体内被血栓调节蛋白(TM)和凝血酶活化后形成活化型PC(APC)介导因子Ⅴa/Ⅷa的灭活并促使血管内皮释放纤溶酶原活化素(PA),发挥抗凝血和促纤溶作用。同时,PC虽不是一种时相反应蛋白,但机体在某些病理状态时可发生显著变化,故可用于临床诊断疾病、观察病情变化及判断预后。国内对PC活性在人群中的分布、正常值及其在各疾病中的病理意义尚缺乏报道。为此。The assay of measuring the anticoagulant activity of protein C (PC) using purified thromo- bomodulin was reported. It was found that the purified thrombomodulin increased the PC acti- vation remarkably by thrombin, and its kinetics data showed that the thrombomodulin was the suitable factor for PC activity detection. The activity of PC in human plasma was detected in 132 healthy persons and 88 patients with malignant cancer by above method. The results indicated that the PC level of patients with liver carcinoma and acute leukemia accompanied with disseminated intravascular coagulation decreased obviously compared with the normal value (P<0.01). On the other hand, plasma PC level turned to nearly normal value in the patients with lymphoma,lung cancer,colon cancer and the like. The pathologic significance of PC activity changes in malignant carcinoma patients was discussed in the paper.

关 键 词：蛋白 肿瘤 凝血酶 抗凝因子 

分 类 号：R730.43[医药卫生—肿瘤]